Biotechnology firm XOMA Corporation (NASDAQ:XOMA) reported on Tuesday that it turned a profit in the fourth quarter following it recorded a one-time gain associated to its dropping stock price.
Xoma’s share price has dropped around 20% since late September, and the firm declared a gain of $16.6M to reflect the cut price of its stock. The firms often take charges when their stock quickly surges in value to reflect better liabilities, and when their stock price plunges; they report one-time gains for the reason that their liabilities are smaller.
Xoma reported that it lost $71.1M, or $1.10 a share, in 2012. The firm declared a smaller loss of $32.7M, or $1.04 a share, in 2011. Its revenue dropped 42%, to $33.8M from $58.2M.
Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose +4.07%, Novavax, Inc. (NASDAQ:NVAX) edged down -0.73%, Galena Biopharma Inc (NASDAQ:GALE) which also increased +5.42% and PharmAthene, Inc. (NYSE:PIP) closed up +10.00%.
XOMA Corporation (NASDAQ:XOMA) stock’s trade at beginning with a price of $3.04 and throughout the trading session climbed at a high of $3.09 other than when day-trade ended the stock finally no change for the day to $3.03.
The stock is going forward its 52 week low with 69.27% and lagging behind from its 52 week high price with -26.63%. XOMA last month stock price volatility remained 4.24%.
XOMA stock institutional ownership remained 66.57% while insider ownership included 0.14%. In its share capital XOMA has 81.56 million outstanding shares among them 78.60 million shares have been floated in market exchange.
Company’s beta coefficient included 2.00. Beta factors measures the amount of market risk associated with market trade.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here